Tyme Inc. (TYME) Reports First Site Open for Phase II Trial with SM-88 in Pancreatic Cancer
Tweet Send to a Friend
Tyme Technologies, Inc. (NASDAQ: TYME) announced today that the first site for the Phase II clinical trial evaluating SM-88 therapy ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
